Intravitreal Pegaptanib in Ischemic CRVO Refractory Exudative Macular Detachment

Research output: Contribution to journalArticlepeer-review


AbstractRecent literature data reported evidence of the visual and/or anatomical benefits of all clinically available anti-VEGFdrugs for the treatment of macular edema (ME) following Central Retinal Vein Occlusion (CRVO), up to 1-year followup.There are no randomized clinical trial data on anti-VEGF agents in ischemic CRVO-ME and the use of anti-VEGFagents to treat this condition.A 73-year old caucasian man, with a medical history of diabetes and systemic hypertension and an ophthalmichistory of ischemic CRVO with cystoid macular edema was referred to our division on January 2011. The ophthalmicexamination showed in right eye a visual acuity of 20/2000, a C2N1 cataract and an exudative macular detachment.On February 2011, a 0.5mg ranibizumab intravitreal injection (Lucentis®, Novartis, Basel, Switzerland) was carried outin the right eye. 15 and 25 days later the OCT showed no changes. On March 2011, we performed a 0.3mg pegaptanibsodium intravitreal injection (Macugen, Eyetech Pharmaceuticals, Inc. and Pfizer Inc, New York, NY) in the right eyeand 15 days later the fluorescein angiography and the OCT examination showed reabsorption of subretinal fluid,complete disappearing of macular detachment and normalization of foveal profile, with a thickness of 240 μm and visualacuity of 20/400. Three months later, foveal profile and visual acuity were unchanged.In our refractory ischemic CRVO-ME patient, pegaptanib sodium showed prompt clinical response. In some cases,even if it is selective for the VEGF165 isoform only, pegaptanib sodium could represent a further possibility in such atherapeutic challenge.
Original languageEnglish
Pages (from-to)1-
Number of pages0
Publication statusPublished - 2012


Dive into the research topics of 'Intravitreal Pegaptanib in Ischemic CRVO Refractory Exudative Macular Detachment'. Together they form a unique fingerprint.

Cite this